Silence Therapeutics plc (NASDAQ:SLN) Expected to Earn Q2 2023 Earnings of ($0.65) Per Share

Silence Therapeutics plc (NASDAQ:SLN – Get Rating) – Investment analysts at William Blair issued their Q2 2023 earnings estimates for Silence Therapeutics in a research report issued to clients and investors on Wednesday, May 17th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.65) for the quarter. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.82) per share. William Blair also issued estimates for Silence Therapeutics’ Q3 2023 earnings at ($0.54) EPS, Q4 2023 earnings at ($0.59) EPS, FY2023 earnings at ($2.14) EPS, FY2024 earnings at ($2.11) EPS and FY2025 earnings at ($2.65) EPS.

Other equities analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Silence Therapeutics in a research note on Friday, March 17th. Robert W. Baird raised their price objective on Silence Therapeutics from $50.00 to $53.00 in a research report on Thursday, January 26th. Morgan Stanley started coverage on Silence Therapeutics in a report on Monday, May 8th. They set an “overweight” rating and a $20.00 price objective on the stock. Finally, Chardan Capital reduced their price target on shares of Silence Therapeutics from $29.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, March 16th.

Silence Therapeutics Price Performance

Shares of NASDAQ:SLN opened at $5.98 on Monday. The company has a market capitalization of $178.97 million, a P/E ratio of -3.83 and a beta of 0.73. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 4.41. The firm’s 50 day simple moving average is $6.77 and its two-hundred day simple moving average is $11.20. Silence Therapeutics has a 1-year low of $4.55 and a 1-year high of $17.99.

Silence Therapeutics (NASDAQ:SLN – Get Rating) last released its quarterly earnings results on Wednesday, March 15th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.91). Silence Therapeutics had a negative net margin of 185.71% and a negative return on equity of 254.24%. The company had revenue of $5.59 million for the quarter, compared to the consensus estimate of $36.30 million.

Institutional Investors Weigh In On Silence Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in Silence Therapeutics in the second quarter worth about $136,000. Schonfeld Strategic Advisors LLC boosted its holdings in Silence Therapeutics by 39.3% during the 1st quarter. Schonfeld Strategic Advisors LLC now owns 41,100 shares of the company’s stock valued at $255,000 after acquiring an additional 11,600 shares during the period. Millennium Management LLC boosted its stake in shares of Silence Therapeutics by 19.8% during the fourth quarter. Millennium Management LLC now owns 17,436 shares of the company’s stock valued at $266,000 after purchasing an additional 2,879 shares during the period. UBS Oconnor LLC lifted its holdings in Silence Therapeutics by 176.4% during the 3rd quarter. UBS Oconnor LLC now owns 79,636 shares of the company’s stock valued at $786,000 after buying an additional 50,820 shares in the last quarter. Finally, UBS Group AG boosted its position in Silence Therapeutics by 4.8% in the 4th quarter. UBS Group AG now owns 69,006 shares of the company’s stock valued at $1,052,000 after buying an additional 3,191 shares during the period.

Silence Therapeutics Company Profile

(Get Rating)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.